Why the study?
Hemostatic management during ECMO requires balancing safe and effective anticoagulation to mitigate thromboembolic complications while minimizing hemorrhagic sequelae.
This review provides an overview of hemostatic management, including pharmacology and monitoring of systemic anticoagulation, to balance thromboembolic and hemorrhagic risks in patients undergoing ECMO.
Anticoagulation in ECMO requires individualized monitoring to balance thrombosis and bleeding; leaves open optimal protocols for prospective trials.
The use of extracorporeal membrane oxygenation (ECMO) for acute cardiac and/or respiratory failure has grown exponentially in the past several decades. Systemic anticoagulation is a fundamental element of caring for ECMO patients. Hemostatic management during ECMO walks a fine line to balance the risk of safe and effective anticoagulant delivery to mitigate thromboembolic complications and minimizing hemorrhagic sequelae. This review discusses the pharmacology, monitoring parameters, and special considerations for anticoagulation in patients requiring ECMO.
No takes yet. Share an insight, caveat, or question.
Brokmeier et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: